Related Experiment Videos
Papillary and follicular thyroid carcinoma
M J Schlumberger1, M Torlantano
1University Paris-Sud, Institut Gustave-Roussy, Rue Camille-Desmoulins, 94805 Villejuif Cedex, France.
Summary
Papillary and follicular thyroid cancers are highly curable, but some patients face high recurrence risk. Early detection and individualized treatment, using serum thyroglobulin and 131I scans, improve outcomes for high-risk thyroid cancer patients.
Area of Science:
- Oncology
- Endocrinology
- Nuclear Medicine
Background:
- Papillary and follicular thyroid carcinomas are generally curable cancers.
- A subset of patients experiences high-risk recurrence or mortality despite initial treatment.
- Prognostic indicators at diagnosis can identify these high-risk individuals.
Purpose of the Study:
- To outline strategies for individualized treatment and follow-up in thyroid cancer.
- To highlight methods for early detection of persistent or recurrent disease.
- To discuss the role of new technologies in patient follow-up and treatment.
Main Methods:
- Utilizing established prognostic indicators for risk stratification at diagnosis.
- Employing serum thyroglobulin measurement for disease monitoring.
- Performing radioactive iodine (131I) total body scanning for detecting persistent/recurrent disease.
- Leveraging recombinant human thyroid stimulating hormone (rhTSH) to enhance diagnostic quality during follow-up.
Main Results:
- Individualized treatment and follow-up plans are crucial for high-risk thyroid cancer patients.
- Combined serum thyroglobulin and 131I scanning effectively detects persistent and recurrent thyroid cancer.
- rhTSH improves patient quality of life during the follow-up period.
Conclusions:
- Risk stratification at diagnosis allows for tailored management of thyroid cancer.
- Early and accurate detection of recurrence is vital for effective intervention.
- Current therapeutic strategies for recurrence primarily involve surgery and 131I treatment.